Nonhematological toxicities in patients included in phase 2
| Adverse event . | All grade (%) . | Grade > 3, % . |
|---|---|---|
| Diarrhea | 6.7 | 0 |
| Fatigue | 16.9 | 0 |
| Musculoskeletal | 33.3 | 0 |
| Stomatitis | 70 | 3 |
| Skin disorders | 36.7 | 0 |
| Bleeding | 13.3 | 0 |
| Hypertriglyceridemia | 70 | 0 |
| Hypercholesterolemia | 23.3 | 0 |
| AST increase | 7 | 3 |
| ALT increase | 7 | 3 |
| Bronchitis | 3 | 0 |
| Pneumonitis | 7 | 7 |
| Urinary tract infection | 7 | 3 |
| Renal failure | 3 | 3 |
| Others | 20 | 0 |
| Adverse event . | All grade (%) . | Grade > 3, % . |
|---|---|---|
| Diarrhea | 6.7 | 0 |
| Fatigue | 16.9 | 0 |
| Musculoskeletal | 33.3 | 0 |
| Stomatitis | 70 | 3 |
| Skin disorders | 36.7 | 0 |
| Bleeding | 13.3 | 0 |
| Hypertriglyceridemia | 70 | 0 |
| Hypercholesterolemia | 23.3 | 0 |
| AST increase | 7 | 3 |
| ALT increase | 7 | 3 |
| Bronchitis | 3 | 0 |
| Pneumonitis | 7 | 7 |
| Urinary tract infection | 7 | 3 |
| Renal failure | 3 | 3 |
| Others | 20 | 0 |
ALT indicates alanine aminotransferase; and AST, aspartate aminotransferase.